A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 156
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IDV
Long Form : indinavir
No. Year Title Co-occurring Abbreviation
2019 Indinavir-Loaded Nanostructured Lipid Carriers to Brain Drug Delivery: Optimization, Characterization and Neuropharmacokinetic Evaluation. BBB, HAART, HIV, NPs, P-gp, PDI, PI, Tr
2019 Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement. IDV-NEs, Lf-IDV-NEs
2017 Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas. BCNU, PHZ, RTV, TMZ
2017 Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. CKD, eGFR, HIV, KD, MDRD
2015 Renal tubular disease in the era of combination antiretroviral therapy. ART, ATV, RTD
2015 Ritonavir-boosted indinavir but not lopinavir inhibits erythrocytic stage Plasmodium knowlesi malaria in rhesus macaques. LPV, RTV
2014 Estimating HIV-1 fitness characteristics from cross-sectional genotype data. HAART, HIV, ZDV
2014 Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format. APV, AZV, DRV, LPV, NFV, RTV, SQV
2014 The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. HIV, HIV-PI, MMP, MT, Sp
10  2014 The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints. NFV, RTV, SQV
11  2012 A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. AUC, MDZ, NIF, PBPK, PK
12  2012 Effect of HIV protease inhibitors on New World Leishmania. ATV, RTV
13  2012 Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. CIN, HAART, HIV, HIV-PIs, MMP, RTV, SQV
14  2012 Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS. LPV, RTV, UPLC-MS-MS
15  2011 Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. AZT, BBB, HAART
16  2011 Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. ATV, HAART, NNRTI, PI, WHO
17  2011 The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors. HIV-1, PI, SQV
18  2011 UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. ATV, EFV, ESI, HIV, RTV
19  2010 Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. AIDS, ddI, HAART, NFV, PI's
20  2010 Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. BMI, CC, OR, RI, VL
21  2009 Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. HIV, UGT
22  2009 Impact of stimulatory pathways on adipogenesis and HIV-therapy associated lipoatrophy. C/EBP, DEX, FCS, IBMX, phsPA, PPAR
23  2009 Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. ART, HIVE
24  2009 Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. RTV
25  2009 Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. ZDV
26  2009 Spectrum of chronic kidney disease in HIV-infected patients. CKD, eGFR, OR, TFV
27  2009 Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine. ABC, NVP, RAM
28  2008 Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. ABC, EFV, EFV-HS
29  2008 HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. HIV, PIs, SOCS-1, ZDF
30  2008 Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. DC, PI
31  2008 Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. AG, CAM, PI
32  2008 Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa. ARV, DDIs, EFV, HIV
33  2008 Two immunomodulators, curcumin and sulfasalazine, enhance IDV antiretroviral activity in HIV-1 persistently infected cells. CUR, SUL
34  2007 Antiretroviral pharmacokinetic profile: a review of sex differences. PIs, RTV, SQV
35  2007 Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. HIV-1, NFV, PIs, SQV
36  2007 Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring. RTV, TDM
37  2007 Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. GM, RTV
38  2007 Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease. HIV-1, NFV, PR
39  2007 HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. ALP, NFV, PI, RTV, SQV
40  2007 Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. PK
41  2007 Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. APV, HIV-2, NFV, PI, PR, TPV
42  2007 Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. LMV, NA, NFV, PK, STV, ZDV
43  2006 Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. ---
44  2006 Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). NRTI, PIs, RTV
45  2006 Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. APV, ATV, CVs, DAD, EFV, LPV, NFV, NVP, RTV, SPE, SQV, TPV
46  2006 Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. ---
47  2006 High prevalence of indinavir-associated renal complications in Thai HIV-infected patients. PI
48  2006 Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. APV, ATV, LPV, OR, SQV, TPV, VR
49  2006 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. PD, PK, RTV
50  2006 Phenotypic resistance of resistant strains of HIV type-1 subtype B in China. HIV-1, NVP
51  2006 Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). ART, NNRTIs, NRTIs, OR, PI, SH, ULN
52  2006 Protease inhibitor effects on triglyceride synthesis and adipokine secretion in human omental and subcutaneous adipose tissue. APV, ASP, OM, PI, RTV, s.c, SQV, TG
53  2006 Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. CI, HAART, LPV, NFV, OR, PI, RTV, SQV
54  2006 Urinary NO3 excretion and renal failure in indinavir-treated patients. ---
55  2006 [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection]. ddI, HAART, NA, PI, RTV
56  2005 Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. HAART, NVP, SNP
57  2005 Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. APV, AUCs, EFV, GMR, NFV, PI, PK, RTV, SQV
58  2005 Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. APV, ATV, EFV, LPV, NFV, RTV, SQV
59  2005 Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment. HIV-1, RTV
60  2005 Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. APV, eNOS, NFV, PIs, RTV, SeMet, SQV
61  2005 Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. ARVs, ddI, HU, NRTIs, PYs
62  2005 Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. ART, RTV
63  2005 Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. ARV, RTV
64  2004 Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. AZT, HIV, LPS, MMPs
65  2004 Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. CF, CQ, MRP1, P-gp, PIs, Rh123, SQV
66  2004 Antiretroviral protease inhibitors prevent l6 muscle cell fusion by reducing calpain activity. HAART, RTV
67  2004 Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. PIs, RTV
68  2004 Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). RTV
69  2004 Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HAART, NFV, PI
70  2004 Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. NLV, PYR, RTV, SQV
71  2004 Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. DOX, HAART, NFV, NHL, SQV
72  2004 Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions. HIV-1, Ig, PBMC, PI
73  2004 Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir. RTV, SQV, VL
74  2004 Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. HIV-1, MM-GBSA, SQV
75  2004 Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. APV, HIV-1, LPV, NFV, PIs, RTV, SQV
76  2004 Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. ABC, COM, LRA, LTORT
77  2004 Simultaneous determination of indinavir, ritonavir and saquinavir in plasma by high-performance liquid chromatography. HPLC, IS, RTV, SQV
78  2004 Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). AT, CIs, COM, ITT, ITT
79  2003 Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. IDV/RTV, ITT, NRTI, OT
80  2003 Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. APV, CsA, HIV, NFV, P-gp, PIs, Rho123, SQV
81  2003 Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. RTV, TID
82  2003 Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. RTI
83  2003 High variability of plasma drug concentrations in dual protease inhibitor regimens. APV, LPV, PIs, RTV, SQV
84  2003 Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. PI
85  2003 Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. MRT
86  2003 Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up. RTV
87  2003 Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir. PIs, RTV
88  2003 Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. AACTG, EFV, NFV, NNRTIs, PD, PIs, PK, SQV
89  2003 Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy. HAART, PI
90  2003 Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. APV, C/EBP, FAS, NFV, SREBP-1
91  2003 The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS. HAART, P-gp
92  2003 The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration. DC, mAb, TEM
93  2003 Vasodilator agents protect against indinavir nephrotoxicity. LA, NF
94  2003 [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir]. PI, RTV, SQV
95  2002 Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. HIV-1, NFV, PIs
96  2002 Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. LPV, PI, RIT, SQV
97  2002 Final analysis of the Trilege induction-maintenance trial: results at 18 months. ZDV
98  2002 Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. APV, FR, LPV, NFV, PI, RI, RTV, SQV
99  2002 Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats. APV, AUC, NFV, PIs, SQV
100  2002 Intracellular accumulation of human immunodeficiency virus protease inhibitors. PIs, RTV, SQV